You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years

Jetsrisuparb, Arunee MD; Komvilaisak, Patcharee MD; Wiangnon, Surapon MD; Jetsrisuparb, Charoon MD

Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181e015b0
Clinical and Laboratory Observations
Abstract

Some iron-overloaded patients have problems being treated with iron chelators. We therefore retrospectively studied 7 iron-overloaded thalassemic patients. Within the same week, patients received 20 to 30 mg/kg/d of oral deferasirox for 4 consecutive days, then a subcutaneous infusion of 20 to 40 mg/kg/d of desferrioxamine for 8 to 12 hours on the next 3 consecutive days. The median treatment duration was 25 months (range, 8 to 32). All of the patients showed a decrease in serum ferritin without any side effects. The protocol, combining deferasirox and desferrioxamine in sequence, was effective and safe: more cases should be studied.

Author Information

Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

This study had no funding support.

Reprints: Arunee Jetsrisuparb, MD, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand (e-mail: arujet@kku.ac.th, arujet@gmail.com).

Received for publication December 15, 2009; accepted March 8, 2010

© 2010 Lippincott Williams & Wilkins, Inc.